retatrutide approval status eli lilly CT Health News | Doctors are warning patients against using unapproved versions of retatrutide, an experimental weight loss drug still in clinical Lilly, with new data, to

Twice-weekly progression showing per-injection mg at each 4-week hold, with IU equivalents at 10mg/mL

Retatrutide (20 mg (lyophilized)) Research Use Only (RUO) Canada About this compound Retatrutide is a triple-agonist peptide targeting GIP, GLP-1, and glucagon receptors simultaneously

A BMI of 27 or higher if you're also dealing with at least one weight-related health issue, like high blood pressure, type 2 diabetes, or high cholesterol

The dose is very small, well below clinical levels, just enough to see how your body reacts before you consider increasing

Retatrutides maximum studied dose is 12mg weekly

Yes, it's a lot